Comparative Pharmacology
Head-to-head clinical analysis: BIAXIN XL versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIAXIN XL versus PEDIAMYCIN 400.
BIAXIN XL vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
500 mg orally once daily for 7 to 14 days
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic